CAI vs ILMN

For growth investors, Caris Life Sciences, Inc.

(CAI) is the stronger pick with 97. 0% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). Illumina, Inc. (ILMN) offers the better valuation at 26. 2x trailing P/E (27. 5x forward), making it the more compelling value choice. Analysts rate Caris Life Sciences, Inc. (CAI) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Illumina, Inc.

is actually cheaper at 27. 5x.

Over the past 5 years, Caris Life Sciences, Inc.

(CAI) delivered a total return of -31. 7%, compared to -61. 1% for Illumina, Inc. (ILMN). Over 10 years, the gap is even starker: ILMN returned +4. 3% versus CAI's -31. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Illumina, Inc.

(ILMN) is the lower-risk stock at 1. 23β versus Caris Life Sciences, Inc. 's 1. 60β — meaning CAI is approximately 29% more volatile than ILMN relative to the S&P 500. On balance sheet safety, Caris Life Sciences, Inc. (CAI) carries a lower debt/equity ratio of 0% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Caris Life Sciences, Inc.

(CAI) is pulling ahead at 97. 0% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -19. 3% for Caris Life Sciences, Inc.. Over a 3-year CAGR, CAI leads at 46. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -66. 2% for Caris Life Sciences, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus 5. 6% for CAI. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Illumina, Inc.

(ILMN) trades at 27. 5x forward P/E versus 158. 8x for Caris Life Sciences, Inc. — 131. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAI: 50. 3% to $28. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Illumina, Inc.

(ILMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 23)). Caris Life Sciences, Inc. (CAI) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ILMN: +4. 3%, CAI: -31. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CAI is a mid-cap high-growth stock; ILMN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.